Lentiviral gene therapy for childhood cerebral X-ALD
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This trial studies an experimental gene therapy given through infusion (IV) and into the spinal fluid (injection) for people with X-ALD affecting the brain. It aims to improve or slow down damage in the nervous system, and you must be able to do MRI scans and meet specific health and infection requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be diagnosed with X-ALD and be at least 1 year old
- Have brain involvement from ALD, based on a blood test called VLCFA levels
- Have a recent brain MRI available for study doctors to review
- Have a neurological function score of 1 or higher
- Be able to give informed consent (or have a parent/guardian consent for a child)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows women with a genetic condition called X-linked adrenoleukodystrophy (ALD) over time to see how the disease progresses. It includes annual check-ups and MRI scans of the brain and spinal cord to monitor changes.
This study checks whether a brain MRI scan can confirm a blood/planning marker that predicts how X-linked adrenoleukodystrophy (ALD) may progress. If you have ALD, it may help researchers better track the condition using safer, non-invasive imaging.
This study collects health information and test results from people with X-linked adrenoleukodystrophy (X-ALD) and some genetic carriers. It helps researchers better understand the condition and how it varies, which can guide future care and studies.
This trial tests a direct gene-therapy injection into the body to treat MLD, a genetic brain condition. It may help replace a faulty gene so the disease process slows or changes.
This trial tests a new gene therapy that uses a patient's own blood stem cells to treat MLD (metachromatic leukodystrophy), a rare genetic disorder that damages the nervous system. The goal is to see if this treatment can stop or slow the disease.
This trial tests a gene therapy made to help people with ADA-SCID (an inherited immune condition caused by a faulty ADA gene). The goal is to improve immune function and reduce severe infections by delivering a working ADA gene into the patient’s own cells.
Hear when a new X-linked Adrenoleukodystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.